Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells $66,227.92 in Stock

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CFO Blaine Davis sold 3,961 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $16.72, for a total value of $66,227.92. Following the sale, the chief financial officer now directly owns 98,839 shares of the company's stock, valued at approximately $1,652,588.08. This represents a 3.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blaine Davis also recently made the following trade(s):

• On Monday, January 6th, Blaine Davis sold 4,028 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.83, for a total value of $67,791.24.

Cartesian Therapeutics Stock Down 2.7 %

Shares of NASDAQ:RNAC traded down $0.47 during trading on Tuesday, reaching $17.16. 105,686 shares of the company traded hands, compared to its average volume of 132,021. The firm has a fifty day simple moving average of $19.32 and a 200 day simple moving average of $18.19. Cartesian Therapeutics, Inc. has a 1-year low of $11.66 and a 1-year high of $41.87. The firm has a market cap of $436.12 million, a P/E ratio of -0.32 and a beta of 0.56.

Analyst Ratings Changes

Several brokerages have commented on RNAC. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price (up from $41.00) on shares of Cartesian Therapeutics in a report on Wednesday, December 4th. BTIG Research began coverage on shares of Cartesian Therapeutics in a research note on Thursday, December 19th. They issued a "buy" rating and a $42.00 price objective for the company. Cantor Fitzgerald raised shares of Cartesian Therapeutics to a "hold" rating in a research note on Monday, December 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $41.00 target price on shares of Cartesian Therapeutics in a research report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $42.86.

Institutional Trading of Cartesian Therapeutics

Institutional investors have recently bought and sold shares of the company. Logos Global Management LP purchased a new stake in shares of Cartesian Therapeutics during the 2nd quarter worth about $2,431,000. FMR LLC grew its stake in shares of Cartesian Therapeutics by 458.3% in the 3rd quarter. FMR LLC now owns 2,851,830 shares of the company's stock valued at $45,972,000 after buying an additional 2,341,054 shares in the last quarter. Marshall Wace LLP acquired a new position in Cartesian Therapeutics in the second quarter worth approximately $811,000. BNP Paribas Financial Markets raised its position in Cartesian Therapeutics by 122.5% during the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company's stock valued at $27,000 after acquiring an additional 909 shares in the last quarter. Finally, State Street Corp lifted its stake in Cartesian Therapeutics by 2.5% in the third quarter. State Street Corp now owns 157,495 shares of the company's stock valued at $2,539,000 after acquiring an additional 3,830 shares during the last quarter. Institutional investors and hedge funds own 86.95% of the company's stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.